Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | IMC-002 |
Synonyms | |
Therapy Description |
IMC-002 is a monocloncal antibody that targets CD47 on tumor cells and inhibits its interaction with signal regulatory protein alpha on phagocytic cells, which may lead to immune cell activation and tumor cell phagocytosis (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
IMC-002 | IMC002|IMC 002 | CD47 Antibody 31 | IMC-002 is a monocloncal antibody that targets CD47 on tumor cells and inhibits its interaction with signal regulatory protein alpha on phagocytic cells, which may lead to immune cell activation and tumor cell phagocytosis (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04306224 | Phase I | IMC-002 | A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas | Completed | USA | 1 |